SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit
3 Medicaid coverage for weight-loss drugs Medicaid is required to provide coverage for any FDA-approved drug that meets the federal definition of a covered outpatient drug and for which the manufacturer has entered into a rebate agreement with the Department of Health and Human Services Secretary (i.e., the Medicaid Drug Rebate Program [MDRP])
While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]
Researchers in the wider research community can view our price list or contact customer support for bulk quantities
The company last weekend abandoned plans to sell a compounded semaglutide pill following warnings from federal regulators as they adopt a tougher stance on copycat weight-loss drugs
Retatrutide vs Tirzepatide: Triple vs Dual Agonist A Researchers Mechanism Comparison For the wider context, see our overview of research peptides for weight loss
